




Population Pharmacokinetics of Intravenous Salbutamol in Children 
with Refractory Status Asthmaticus
Nienke J. Vet1  · Brenda C. M. de Winter2 · Muriel Koninckx3 · Shelley A. Boeschoten1 · Annemie L. M. Boehmer4 · 
Jacintha T. Verhallen5 · Frans B. Plӧtz6 · Anja A. Vaessen‑Verberne7 · Bart C. H. van der Nagel2 · 
Catherijne A. J. Knibbe8 · Corinne M. P. Buysse1 · Saskia N. de Wildt1,9 · Birgit C. P. Koch2 · Matthijs de Hoog1
 
© The Author(s) 2019
Abstract
Background Intravenous salbutamol is used to treat children with refractory status asthmaticus, however insufficient phar-
macokinetic data are available to guide initial and subsequent dosing recommendations for its intravenous use. The pharma-
cologic activity of salbutamol resides predominantly in the (R)-enantiomer, with little or no activity and even concerns of 
adverse reactions attributed to the (S)-enantiomer.
Objective Our aim was to develop a population pharmacokinetic model to characterize the pharmacokinetic profile for 
intravenous salbutamol in children with status asthmaticus admitted to the pediatric intensive care unit (PICU), and to use 
this model to study the effect of different dosing schemes with and without a loading dose.
Methods From 19 children (median age 4.9 years [range 9 months–15.3 years], median weight 18 kg [range 7.8–70 kg]) 
treated with continuous intravenous salbutamol at the PICU, plasma samples for R- and S-salbutamol concentrations (111 
samples), as well as asthma scores, were collected prospectively at the same time points. Possible adverse reactions and 
patients’ clinical data (age, sex, weight, drug doses, liver and kidney function) were recorded. With these data, a population 
pharmacokinetic model was developed using NONMEM 7.2. After validation, the model was used for simulations to evalu-
ate the effect of different dosing regimens with or without a loading dose.
Results A two-compartment model with separate clearance for R- and S-salbutamol (16.3 L/h and 8.8 L/h, respectively) 
best described the data. Weight was found to be a significant covariate for clearance and volume of distribution. No other 
covariates were identified. Simulations showed that a loading dose can result in higher R-salbutamol concentrations in the 
early phase after the start of infusion therapy, preventing accumulation of S-salbutamol.
Conclusions The pharmacokinetic model of intravenous R- and S-salbutamol described the data well and showed that a 
loading dose should be considered in children. This model can be used to evaluate the pharmacokinetic–pharmacodynamic 
relationship of intravenous salbutamol in children, and, as a next step, the effectiveness and tolerability of intravenous sal-
butamol in children with severe asthma.
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Key Points 
In this prospective study, we developed a population 
pharmacokinetic model of intravenous R- and S-salbuta-
mol in children with status asthmaticus admitted to the 
intensive care unit.
The model described the data well and showed that 
a loading dose seems valid to reach higher initial 
R-salbutamol concentrations with a possible therapeutic 
advantage.
This model can be used to evaluate the pharmacoki-
netic–pharmacodynamic relationship of intravenous 
salbutamol.
 N. J. Vet et al.
1 Introduction
Asthma exacerbations are a frequent cause of hospitalization 
among children, with admissions for refractory status asth-
maticus to intensive care increasing over the last years [1, 2]. 
The pathologic hallmarks of asthma are bronchoconstriction, 
airway inflammation, and mucus plugging, all of which may 
lead to severe airflow obstruction.
The initial therapy of status asthmaticus includes oxy-
gen, repetitive administration of inhaled β2-agonists and 
ipratropium, and systemic corticosteroids. The aim of these 
treatments is to improve airflow obstruction and hypoxemia 
as quickly as possible. For patients who do not respond to 
initial therapy, magnesium sulphate, aminophylline and 
intravenous salbutamol are suggested [3]. Depending on 
local or national guidelines, intravenous salbutamol is used 
as second- or third-line treatment. Intensive care admission 
is often needed for continuous monitoring [3, 4]. Intrave-
nous salbutamol may be more effective in severe asthma as 
delivery of inhaled drugs to airways may be attenuated and 
unpredictable as a result of severe airflow obstruction [5].
Salbutamol (albuterol) is a selective β2-adrenoreceptor 
agonist with potent smooth muscle relaxant properties, and 
is a chiral compound with (R)- and (S)-enantiomers. The 
pharmacologic activity of salbutamol resides predominantly 
in the (R)-enantiomer, with little or no activity attributed to 
the (S)-enantiomer [6]. Moreover, there are concerns that 
particularly high exposure to S-salbutamol may have nega-
tive effects. The primary route of elimination of salbutamol 
is by sulfate conjugation (SULT1A3), followed by renal 
excretion. Up to 50% of salbutamol is excreted unchanged 
in urine [7]. The elimination of (R)-salbutamol is much more 
rapid than that of (S)-salbutamol, which leads to relatively 
higher plasma concentrations of (S)-salbutamol with the 
same continuous infusion [8].
Although intravenous salbutamol is often used in chil-
dren, pharmacokinetic (PK) data are scarce. Dosing recom-
mendations are not based on well-conducted PK and phar-
macodynamic (PD) studies and, as a result, guidelines are 
inconsistent with respect to salbutamol dosing in children. 
Dosing of intravenous salbutamol in children varies between 
0.1 and 10 μg/kg/min and there is no consensus on the need 
for a loading dose at the start of therapy [9–11]. Compared 
with adult dosing, these recommendations are higher and 
might lead to toxic serum concentrations. PK data are 
needed to guide initial and subsequent dosing recommen-
dations for intravenous salbutamol in children. Therefore, 
the aim of this study was to develop a population PK model 
to characterize the PK profile for intravenous salbutamol in 
children with status asthmaticus admitted to the intensive 
care unit.
2  Methods
2.1  Patients and Setting
For this PK study, patients were recruited from Erasmus 
MC-Sophia Children’s Hospital’s pediatric intensive care 
unit (PICU), a tertiary PICU in The Netherlands. Approval 
was obtained from the Institutional Review Board, along 
with written informed consent from parents or legal repre-
sentatives and patients (12–18 years).
Eligible patients were children with status asthmaticus 
aged between 0 and 18 years of age who were admitted to 
the PICU because of respiratory distress and who required 
intravenous salbutamol. Those patients requiring extracor-
poreal membrane oxygenation were excluded from the study.
Patients were treated according to our institutional clini-
cal protocol for status asthmaticus (electronic supplementary 
Appendix I). A continuous salbutamol infusion was started 
at a rate of 0.1 μg/kg/min. Subsequently, the infusion rate 
was increased every 10 min depending on clinical symptoms 
(wheezing, dyspnoe, saturation) and asthma score, with a 
maximum infusion rate of 10 μg/kg/min (electronic supple-
mentary Appendix I).
2.2  Measurements
Blood for salbutamol concentrations was sampled using an 
optimized sampling strategy for PK analysis. Ideally, the 
first blood sample was taken before the start of intravenous 
salbutamol (plasma drug level after inhaled salbutamol 
only), but because of the acute setting at admission to the 
Emergency Department or PICU, and no informed consent 
having been received at that point in time, the first blood 
sample was only available if leftover material taken from 
clinical care was available. During the infusion of salbuta-
mol, serial blood samples were taken at time points of 10, 
15–30, 40–60 min, 2–4, 4–6 and 8–16 h after an infusion 
rate change. Further samples were taken prior to discon-
tinuation, as well as 10, 30–60 min, 2–6 and 12–24 h after 
discontinuation of the infusion. Blood (0.5 mL) was drawn 
from an indwelling arterial line or central venous catheter, 
or, in case this was not available, together with peripheral 
blood sampling for clinical purposes. Plasma samples were 
analysed for R- and S-salbutamol concentrations separately 
using a validated liquid chromatography–tandem mass spec-
trometry (LC-MS/MS) method; the limit of quantification 
of the method was 1.0 µg/L, with a linearity of between 1.0 
and 500 µg/L for both R- and S-salbutamol (electronic sup-
plementary Appendix II).
As a PD parameter, the Qureshi asthma score was col-
lected at the same time points as blood sampling. This vali-
dated score is routinely used in the intensive care unit to 
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monitor symptom progression [12, 13]. It is a 5-item scale 
(breathing frequency [categories for age], oxygen saturation, 
auscultation, retractions and dyspnea), with a minimum of 
1 and maximum of 3 for each item, resulting in a range of 
5–15. A higher score indicates a more severe exacerbation. 
Possible adverse reactions from salbutamol, such as tachy-
cardia, arrhythmias, hypotension, hypokalemia, hyperglyce-
mia and lactic acidosis were recorded.
Furthermore, age, bodyweight, sex, diagnosis, drug 
doses, and available kidney and liver function indices were 
collected for all patients from our computer-based patient 
data management system.
2.3  Population Pharmacokinetic (PK) Model
The population PK model was developed using nonlinear 
mixed-effects modelling (NONMEM, version 7.2; ICON 
Development Solutions, Ellicott City, MD, USA). The analy-
sis was performed using logarithmically transformed con-
centrations and the first-order conditional estimation method 
with interaction (FOCE-I) [ADVAN5 TRANS1]. Tools used 
to evaluate and visualize the model were RStudio (version 
0.98.1049), R (version 3.1.2), XPose (version 4.5.3) and PsN 
(version 4.6.0), all with the graphical interface Pirana (ver-
sion 2.9.0) [14].
Model development was a three-step process: (1) selec-
tion of a structural and error model; (2) covariate analysis; 
and (3) internal validation of the model.
In the first step, a structural model was developed to 
describe the PK of R- and S-salbutamol. The salbutamol 
concentration before the start of the intravenous concentra-
tion related to the inhalation therapy was estimated based 
on the available data. The concentration at this time was 
estimated assuming an equal distribution between R- and 
S-salbutamol. For each patient, the baseline concentration 
was estimated using a parameter for the baseline dose, 
with interpatient variability (IPV). To determine the struc-
tural PK model, one- and two-compartment models were 
tested for both enantiomers. PK parameters were estimated 
in terms of central volume of distribution (Vc), peripheral 
volume of distribution (Vp), clearance (CL), and intercom-
partmental clearance (Q). For each parameter, it was deter-
mined whether the parameter could be estimated for both 
enantiomers together, or whether it had to be estimated 
separately. To account for the variability in PK param-
eters due to the varying size of the individual children, 
the parameter values were standardized to a body weight 
of 70 kg using allometric scaling, in which the exponen-
tial parameter was initially fixed at a value of 0.75 for 
CL and Q, and a value of 1 for the volumes of distribu-
tion [15]. During the covariate analysis, it was evaluated 
whether estimation of the exponent improved the goodness 
of fit. The addition of IPV, described using an exponen-
tial model, was evaluated for each PK parameter. Residual 
variability between observed and predicted plasma con-
centrations was described using an additional error model 
for logarithmically transformed data.
Once the base model was selected, covariates were 
tested for their influence on PK parameters. Covariates 
tested were bodyweight (estimation of exponent for allo-
metric scaling), age, sex, creatinine, alanine transami-
nase, and urea concentrations. Continuous covariates 
were normalized to the population median and modeled 
using an exponential model, while categorical variables 
were modelled proportionally. Covariates were included 
using forward inclusion (p < 0.05) and backward elimina-
tion (p > 0.001). Additional criteria for the inclusion of 
covariates in the model were graphical evaluation of the 
parameter–covariate relationship and decrease in the IPV 
of the parameter involved.
The minimum objective function value (OFV) was used 
as a criterion for model selection. If the difference between 
two nested models was larger than the critical value from 
a Chi-square distribution with degrees of freedom equal 
to the difference in the number of estimated parameters, 
the models were significantly different from each other. A 
decrease in OFV > 10.83 showed a significant improve-
ment of a nested model with one degree of freedom of 
p < 0.001. Model adequacy was further evaluated using 
various residual plots (‘goodness-of-fit’ plots) stratified 
for age groups < 5, 5–10 and > 10 years, and values of 
random-effects variances.
The final model was validated using normalized predic-
tion distribution errors (NPDEs), using 2000 simulated data-
sets. This is a simulation-based diagnostic, which can be 
used to evaluate models developed on datasets with variable 
dosing regimens.
2.4  Dose Simulations
After validation, the model was used for simulations to eval-
uate the effect of different dosing regimens with or without a 
loading dose. The R- and S-salbutamol concentrations were 
simulated using the final model for a typical child weigh-
ing 15 kg. As a result of salbutamol inhalation therapy, a 
concentration of approximately 20 μg/L was observed just 
before the start of the intravenous administration. The intra-
venous salbutamol administration is started as well as this 
salbutamol concentration, which is described by the model 
using the baseline dose. The intravenous infusion rate in the 
first 10 min varied between 0.5 (no loading dose) and 1.5 μg/
kg/min (with loading dose), followed by a continuous infu-
sion of 0.5 μg/kg/min for the following 6 h.
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3  Results
3.1  Patients and Data
Salbutamol concentrations were obtained from 19 children 
treated with intravenous salbutamol at the PICU between 
September 2011 and February 2013. Patients were between 
9 months and 15 years of age (median 4.9 years) and body 
weight ranged from 7.8 to 70  kg (median 18  kg) (see 
Table 1).
A total of 117 plasma samples were analyzed for R- and 
S-salbutamol. In 8 of the 117 samples obtained from seven 
different patients, extremely high concentrations of both 
enantiomers were measured. Six of these concentrations 
could be explained due to skin contamination of fingerprick 
blood after nebulizing salbutamol [16]. These samples were 
subsequently removed from the database, resulting in a final 
dataset containing 111 samples (median of three samples per 
patient, range 1–22).
For eight patients, plasma samples were taken during 
inhalational salbutamol therapy and shortly before the start 
of intravenous salbutamol. The median plasma level of 
R-salbutamol (n = 8) was 24.5 μg/L (range 7–60 μg/L), 
and 49 μg/L (range 31–94 μg/L) for S-salbutamol. Median 
plasma levels during intravenous salbutamol were 66 μg/L 
(range 4–969 μg/L) for R-salbutamol and 108 μg/L (range 
19–1094 μg/L) for S-salbutamol (see electronic supple-
mentary material 1). The median dose range was 0.96 μg/
kg/min (range 0.07–10 μg/kg/min), and the maximum dose 
of 10 μg/kg/min was administered to two patients. The 
median duration of intravenous therapy was 22.5 h (range 
7.6–192.5 h). Asthma scores were between 5 and 15, with 
a median score of 8 during the whole study period. At the 
time when patients were sickest, the median score was 
12 (range 9–15). No simple graphical correlation between 
asthma scores and salbutamol concentration was found, 
and no major adverse reactions were reported.
3.2  Population PK Model
Data could best be described using a two-compartment 
model, with separated clearances for R- and S-salbutamol 
(Fig. 1). Immediately after infusion, salbutamol is divided 
towards two central compartments (k = 10 h−1 fixed), with 
equal volumes of distribution of 12.9 L for both enantiom-
ers. The covariate analysis showed that body weight was 
a significant covariate using a power function. The expo-
nent of the power function was fixed at 0.75 for clearance 
and Q, and at 1 for Vc and Vp. Estimation of the exponent 
resulted in similar values and did not improve the model. 
The parameter estimations are presented in Table 2. No 
other covariates resulted in a significant improvement of 
the model. Goodness-of-fit plots showed a good fit of the 
model (Fig. 2). This final model resulted in a  CLR-salbutamol 
of 5.13 L/h,  CLS-salbutamol of 2.78 L/h, and Vc of 2.76 L for 
a typical child weighing 15 kg.  
3.3  Model Evaluation
The model was evaluated using a bootstrap analysis. Median 
parameter values, as well as the 5th and 95th percentiles, 
were in agreement with the model estimations and errors. 
The distribution of errors was close to normal in the NPDEs 
(electronic supplementary material 2), with no significant 
trends in NPDE versus time and NPDE versus predictions.
3.4  Dose Simulations
The simulation in Fig. 3 shows that a loading dose leads to 
higher R- and S-salbutamol concentrations in the first hour 
after the start of intravenous salbutamol, compared with the 
infusion without a loading dose. The infusion rate of 0.5 μg/
kg/min without a loading dose resulted in R-salbutamol con-
centrations of 22.2 μg/L and S-salbutamol concentrations 
Table 1  Patient characteristics (n = 19)
Parameter Median Range
Age (years) 4.9 0.8–15.3
Bodyweight (kg) 18 7.8–70
Sex (male/female) 14/5
Creatinine (μmol/L) 29 17–70
Alanine transaminase (IU/L) 15 5–26
Urea (mmol/L) 3.2 1.6–4.8
Salbutamol intravenous dose (μg/kg/min) 0.96 0.07–10
Duration of intravenous salbutamol (h) 22.5 7.6–192.5
Fig. 1  Compartmental model. After intravenous infusion, salbutamol 
was rapidly split into 50% R-salbutamol and 50% S-salbutamol. Both 
had the same Vc, Vp and Q in a two-compartment system, as well as 
different values for CL. CL clearance, IV intravenous, Q intercom-
partmental clearance, Vc central volume of distribution, Vp peripheral 
volume of distribution
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Table 2  Parameter estimations
Vc, Vp and Q were identical for R- and S- salbutamol
A typical child weighing 15  kg will have a  CLR-salbutamol of 16.3 × (15/70)0.75 = 5.13  L/h,  CLS-salbutamol of 
8.82 × (15/70)0.75 = 2.78 L/h, and Vc = 12.9 × (15/70)1 = 2.76 L
CL clearance, IPV interpatient variability, Q intercompartmental clearance, RSE relative standard error, Vc 
central volume of distribution, Vp peripheral volume of distribution
Parameter Estimation RSE (%) IPV (%) RSE (%) Shrinkage (%)
Baseline dose (μg) 448 25 99 20 15
CLR-salbutamol (L/h/70 kg) 16.3 12.4 42 15 19
CLS-salbutamol (L/h/70 kg) 8.82 10.4 37 16 23
Vc (L/70 kg) 12.9 65 281 21 9
Q (L/h/70 kg) 20.4 41.5
Vp (L/70 kg) 45.5 9.6
Residual error (μg/L) 0.351 21.9 6
Fig. 2  Goodness-of-fit plots of R-salbutamol (black) and S-salbutamol (grey)
 N. J. Vet et al.
of 29.2 μg/L at 15 min after the start of infusion therapy. 
With a loading dose, the R-salbutamol concentration was 
36.7 μg/L and the S-salbutamol concentration was 45.7 μg/L 
at 15 min. Longer treatment with intravenous salbutamol 
results in increasing concentrations of mainly S-salbutamol.
4  Discussion
In this prospective study, we developed a population PK 
model of intravenous R- and S-salbutamol in children with 
status asthmaticus admitted to the intensive care unit. This 
model described the data well and showed that a loading 
dose seems valid in order to reach higher initial R-salbuta-
mol concentrations with a possible therapeutic advantage. 
Furthermore, this model can be used to evaluate the PK-PD 
relationship of intravenous salbutamol.
Current dosing recommendations for intravenous salbu-
tamol in children are not based on age-appropriate PK-PD 
data but are derived from adult data only [11]. There is no 
clear agreement about the initial dose of salbutamol required 
by the intravenous route in acute situations in children. For 
example, the Dutch pediatric formulary does not recommend 
a loading dose, but does recommend an initial continuous 
infusion of 0.1–10 μg/kg/min (http://www.kinde rform ulari 
um.nl), while the British National Formulary recommends a 
bolus dose of 15 μg/kg (maximum 250 μg) over 5 min and a 
continuous infusion of 1–5 μg/kg/min. In contrast, the Brit-
ish guideline on the management of asthma [3] recommends 
administering the same bolus dose in 10 min rather than 
5 min. Despite these guidelines, a survey in the UK and 
Ireland showed a threefold and tenfold variation in bolus 
doses and continuous infusion rates, respectively, reflecting 
the paucity of evidence to support dosing of intravenous 
salbutamol [17].
As intravenous salbutamol is delivered systemically, 
there are concerns that it is more likely to produce systemic 
adverse reactions related to interaction with non-airway 
β1 receptors, such as tachycardia and dysrhythmias, than 
inhaled salbutamol. However, data on toxicity related to dose 
or serum concentrations are scarce. After multiple doses of 
inhaled salbutamol, plasma concentrations of 20–40 ng/
mL were found in adults and children [18–20]. In adults, 
salbutamol toxicity is associated with plasma concentra-
tions > 30 ng/mL [21]; however, in children receiving intra-
venous salbutamol according to current guidelines, much 
higher systemic salbutamol concentrations (196–586 ng/mL) 
have been recorded [22, 23]. In our study, we also found 
higher median plasma levels of R-salbutamol (66 μg/L, 
range 4–969  μg/L) and S-salbutamol (108  μg/L, range 
19–1094 μg/L) than reported in adults, with no associated 
adverse reactions (data not shown), however our study popu-
lation was small. There is a need to establish a therapeutic 
plasma concentration range in children.
After inhalation only, plasma levels were 24.5  μg/L 
(range 7–60 μg/L) for R-salbutamol and 49 μg/L (range 
31–94 μg/L) for S-salbutamol, consistent with previous 
reports.
The necessity of an intravenous loading dose of salbu-
tamol is currently under discussion. In adults, salbutamol 
has a half-life of 4–6 h after intravenous administration. 
As it takes approximately four half-lives to reach a plateau 
concentration if a drug is given as a constant infusion, 
12–24 h is required to reach a plateau concentration, and 
subtherapeutic levels will be observed at the beginning 
of therapy, combined with excessive levels after several 
hours, if the infusion is titrated upwards according to clini-
cal signs. An appropriate loading dose will result in faster 
target concentrations.
In children, the advice regarding loading dose is based 
on a few studies looking at the effect of a bolus dose of 
intravenous salbutamol 10–15 μg/kg [24, 25] on asthma 
scores and hospital admission. These studies show a small 
effect on time to discharge from hospital or the PICU, 
duration of nebulization of salbutamol, and clinical asthma 
scores; however, no study used a validated asthma score 
and all studies had several methodological shortcomings. 
Furthermore, the patients in these studies did not receive 
a continuous infusion of intravenous salbutamol after the 
salbutamol loading dose.
Using our PK model, simulations of intravenous sal-
butamol in children with refractory status asthmaticus 






















Fig. 3  Simulation of R-salbutamol (solid lines) and S-salbutamol 
(dotted lines) concentrations for a child weighing 15 kg, after a con-
tinuous intravenous salbutamol infusion of 0.5  μg/kg/min without a 
loading dose (light grey), or after a loading dose of 1.0  μg/kg/min 
(dark grey) or 1.5  μg/kg/min (black) over 10  min. The initial con-
centration before infusion is almost 20 μg/L as a result of salbutamol 
inhalation
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showed that a loading dose of salbutamol results in faster 
desired concentrations. In our simulations, we showed that 
a loading dose of 1.5 μg/kg/min over 10 min (15 μg/kg), 
followed by a continuous infusion of salbutamol 0.5 μg/kg/
min, is required to reach an R-salbutamol concentration of 
40 μg/L in a child weighing 15 kg. Because of the half-life 
of salbutamol found in our model (for a 15 kg child, the 
half-life of R-salbutamol was 22 min, and 41 min for S-sal-
butamol), a loading dose needs to be considered to quickly 
reach effective R-salbutamol concentrations in the early 
phase after the start of infusion therapy, thereby aiming for 
faster clinical improvement. Furthermore, a loading dose 
prevents accumulation of S-salbutamol, which is important 
as there are concerns that particularly high exposure to 
S-salbutamol may have negative effects. In vitro, animal 
studies and studies in patients with mild asthma suggest 
that S-salbutamol may increase bronchial hyperreactiv-
ity and promote smooth muscle contraction, leading to 
more respiratory distress [26–29], although this is under 
discussion [30]. As expected, we found a lower clearance 
of S-salbutamol compared with R-salbutamol. Knowledge 
of the PK of both R- and S-salbutamol is important to 
find the optimal dose for bronchodilation without adverse 
reactions.
Some limitations of our study should be acknowledged. In 
contrast to an earlier study [7], we found no effect of creati-
nine on salbutamol clearance, which is most likely due to the 
small number of patients and the absence of renal dysfunc-
tion in our cohort. Furthermore, we chose not to explore the 
relationship of genetic polymorphisms of the ADRB2 gene 
on salbutamol clearance as our sample size was very small.
An important strength of our study is that we took prior 
inhaled drugs into account in our model. Earlier studies 
did not measure plasma drug level after inhalation, while 
it is known that there is a significant degree of absorption 
of inhaled drugs. In clinical practice, children with severe 
asthma have had several inhaled doses of salbutamol prior 
to commencing intravenous drug therapy.
5  Conclusions
This PK model could be a first step towards evidence-based 
dosing of intravenous salbutamol in children. Simulations 
showed that a loading dose should be considered in children 
to quickly reach effective R-salbutamol concentrations in 
the early phase after the start of infusion therapy, thereby 
aiming for faster clinical improvement. As a next step, the 
efficacy of a loading dose of intravenous salbutamol should 
be studied in children with severe asthma, in a randomized 
controlled trial, compared with placebo (NCT03493503).
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